Sort
16,179 grants matching “malaria”
TULANE NATINAL PRIMATE RESEARCH CENTER
$1,082,820Paul K Whelton · Tulane University Of Louisiana · P51 · FY2006 · RR
India International Center for Excellence in Research
$1,082,746Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
SickleGenAfrica:Sickle Cell Disease Genomics Network of Africa
$1,081,887Solomon Fiifi Ofori-Acquah · University Of Ghana · U54 · FY2018 · HL
The Aedes aegypti Genome Project
$1,081,017University Of Notre Dame · U01 · FY2002 · AI
Malaria Drug Resistance and Disease Virulence
$1,080,355Thomas E Wellems · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
India International Center for Excellence in Research
$1,080,177Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESOURCE REPOSITORY (MID-BRR)
$1,080,000James McArdle · American Type Culture Collection · N01 · FY2011 · AI
Center for the Study of Complex Malaria in India
$1,079,922Jane Carlton · New York University · U19 · FY2023 · AI
Use of Bacteriophages to Prevent, Diagnose, and Treat Diseases
$1,079,030Sankar Adhya · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Environmental Modifications in sub-Saharan Africa: Changing Epidemiology, Transmission and Pathogenesis of Plasmodium falciparum and P. vivax Malaria
$1,078,950Guiyun Yan · University Of California-Irvine · U19 · FY2021 · AI
Impact of Environmental Modifications on Plasmodium falciparum and P. vivax Malaria Epidemiology and Disease Burden
$1,078,950Beyene Petros · University Of California-Irvine · U19 · FY2021 · AI
Impact of Environmental Modifications on Pathogenesis and Immunity of Plasmodium falciparum and P. vivax Malaria
$1,078,945James Walter Kazura · University Of California-Irvine · U19 · FY2023 · AI
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine LC3
$1,077,287Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Development and Production of Anti-Malarial Biologicals
$1,077,167Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2020 · AI
Development of Antimalarial Preclinical Candidates
$1,076,671R Kiplin Guy · St. Jude Children'S Research Hospital · U01 · FY2009 · AI
DRW HIV-Ab/HCV-Ab/HBsAg Triplex Rapid Test Submission for FDA-PMA Approval
$1,075,162Helen H Lee · Diagnostics For The Real World, Ltd · R44 · FY2010 · HL
ERIN CRC: Molecular Basis of Nontyphoidal Salmonella Emergence
$1,073,834Samuel I. Miller · University Of Washington · U19 · FY2013 · AI
Center Based Initiative #2 (Florida)
$1,072,582Patrick Robert Griffin · Scripps Research Institute, The · U54 · FY2010 · MH
Development of Malaria Transmission-Blocking Drugs
$1,071,030Philip Sanderson · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
STRENGTHENING NATIONAL CAPACITY IN MALARIA AND OTHER INFECTIOUS DISEASE OPERATION
$1,070,000Don P Mathanga · University Of Malawi · U01 · FY2011 · CK
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,069,709Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2008 · AI
Genomic and environmental risk factors for cardiometabolic disease in Africans
$1,068,144Michele Michele Ramsay · Wits Health Consortium (Pty), Ltd · U54 · FY2014 · HG
COBRE for Perinatal Biology
$1,068,127James F Padbury · Women And Infants Hospital-Rhode Island · P30 · FY2015 · GM
Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia
$1,067,899Cindy S Chu · University Of Oxford · U01 · FY2023 · AI
Development of an anti-malaria toxin vaccine candidate
$1,067,392William J Christ · Ancora Pharmaceuticals, Inc. · R44 · FY2006 · AI